JAK2 and lung carcinoma: Research has demonstrated that abnormal JAK2/STAT3 signaling pathway activation occurs in lung cancer and other tumor tissues and tumor cells and it is engaged in the occurrence, metastasis, development, and invasion of tumors [29].